Cometriq cabozantinib: Phase II data

Data from 16 patients with advanced ret proto-oncogene ( RET)-rearranged NSCLC in stage 1 of a 2-stage, open-label, investigator-initiated, U.S. Phase II trial showed that once-daily 60 mg Cometriq m...